1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview, CHI Insight Pharma Reports

Available to Insight Pharma Reports is Ocular Disorders: Rising Therapeutics, Technologies, and Devices Report. This report begins with outlining Age-related macular degeneration (both wet and dry) and delving into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, their strategies for seeking alternative therapeutic options, and the hardships they have encountered in their research and product execution.

Report highlights include:

Exclusive interviews from four companies (Oraya Therapeutics, VisionCare Ophthalmic Technologies, Omeros, and Kala Pharmaceuticals) providing details of their products.
Both invasive and noninvasive procedures are discussed, along with current treatment options and how they relate to rising therapies.
Demographic survey and analysis of researchers working in ocular disorders including promising therapeutic options, targets of interest, and challenges encountered.
Over 250 companies featuring clinical trials and pipeline data.

Table Of Contents

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview, CHI Insight Pharma Reports
CHAPTER 1: Age-Related Macular Degeneration

Wet AMD

Dry AMD

CHAPTER 2: Therapeutic Efficacy

Anti-VEGF therapies

Pegaptanib
Bevacizumab
Ranibizumab
VEGF Trap-EYE
CHAPTER 3: Oraya Therapeutics

Radiotherapy platform

Automatic Positioning System (APS)
I-Guide
System software
Radiation dosing

Potential complications and risk factors

Competitive advantage

Challenges and areas of improvement

Future expectations

Interview with Jim Taylor

Radiation therapy
Competitive advantage
Challenges encountered
Areas of improvement
Future expectations
CHAPTER 4: VisionCare Ophthalmic Technologies

Company background

Telescope technology

Complications and challenges

Interview with Reena Mishra

Company background
Telescope technology
Competitive advantage
Complications and challenges
CHAPTER 5: Omeros

Company background

PharmacoSurgery platform

Pipeline

Competitive advantage

Challenges encountered

Validation

Future expectations

Interview with Greg Demopulos

Company background
PharmacoSurgery platform
OMS302
Competitive advantage
Challenges encountered
Validation procedure
Future expectations
CHAPTER 6: Kala Pharmaceuticals

Company background

Mucosal penetrating products (MPP)

Competitive advantage

Future endeavors

Interview with Kim Brazzell

Company background
Mucosal penetrating products (MPP)
Challenges encountered
Competitive advantage
Future endeavor
CHAPTER 7: Platforms and Products

CHAPTER 8: Survey of Ocular Industry

Areas of development

Promising targets and therapies

Challenges encountered

CHAPTER 9: Clinical Trials and Pipeline Data

References

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.